眼部炎症系统免疫调节治疗后发生组织胞浆菌病
该回顾性病例系列研究分析了1994至2017年Mayo Clinic收治的9例接受系统免疫调节治疗(IMT)后发生肺或播散性组织胞浆菌病的葡萄膜炎或巩膜炎患者,并与3:1年龄性别匹配的对照组比较。结果显示多数病例需系统抗真菌治疗,但可能无需停用IMT,且IMT时长与风险无相关性。
要点
- 接受系统IMT的眼部炎症患者可能发生肺或播散性组织胞浆菌病。
- 多数病例需系统抗真菌治疗,但可能无需停用IMT。
- 眼科医生应警惕IMT患者组织胞浆菌感染风险增高。
核心结论
- 接受系统免疫调节治疗的眼部炎症患者可能发生肺或播散性组织胞浆菌病。
- 多数病例需系统抗真菌药物治疗,但可能无需停用系统免疫调节药物。
研究设计与样本
- 回顾性病例系列,纳入1994年9月1日至2017年7月1日Mayo Clinic Rochester的葡萄膜炎或巩膜炎后发生肺或播散性组织胞浆菌病患者。
- 设3:1年龄性别匹配对照,对照为接受系统IMT治疗眼部炎症但未发生组织胞浆菌病者。
主要发现
- 共识别9例组织胞浆菌病:2例播散性,7例肺型。
- 2例播散性患者均在使用肿瘤坏死因子α抑制剂。
- 9例中7例接受系统抗真菌药物,包括2例播散性病例。
- 中位随访4.4年期间无死亡,无组织胞浆菌病复发。
- 与对照组相比,IMT使用时长与组织胞浆菌病风险无相关性。
临床怎么用
- 眼科医生应意识到接受系统IMT的患者发生组织胞浆菌感染的风险较高。
- 及时诊断并借助感染病专科 expertise 治疗可能确保低死亡率。
局限性
- 单中心回顾性研究,样本量小(9例病例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Histoplasmosis is a known complication of systemic immunosuppressive therapy, particularly among patients who are receiving tumor necrosis factor α inhibitors. There are limited data on the development of disseminated or pulmonary histoplasmosis among patients who are receiving systemic immunosuppressive medication for noninfectious ocular inflammation. DESIGN: Retrospective case series. METHODS: We reviewed all patients with uveitis or scleritis who subsequently developed pulmonary or disseminated histoplasmosis at the Mayo Clinic in Rochester, Minnesota between September 1, 1994 and July 1, 2017, with a 3:1 age- and sex-matched control cohort who did not develop histoplasmosis. This was a single institutional study examining patients that developed histoplasmosis after the initiation of systemic immunomodulatory therapy (IMT). Patients had to develop either disseminated or pulmonary histoplasmosis while receiving systemic immunosuppressive therapy and have an ophthalmic examination at Mayo Clinic Rochester. The control group was comprised of patients who received systemic IMT for ocular inflammation but did not develop histoplasmosis. RESULTS: Nine cases of histoplasmosis were identified: 2 disseminated and 7 pulmonary. Both patients with disseminated histoplasmosis were taking tumor necrosis factor α inhibitors. Seven of the 9 patients received systemic antifungal medication, including both disseminated cases. Over a median follow-up of 4.4 years, none of the patients died, and there were no recurrences of histoplasmosis. When compared to the control cohort, there was no correlation between length of time on IMT and the risk of histoplasmosis. CONCLUSIONS: Ocular inflammation patients on systemic immunomodulatory therapy may develop pulmonary or disseminated histoplasmosis. Most cases require treatment with systemic antifungal medication, but it might not be necessary to stop systemic immunomodulatory medication for ocular inflammation. Ophthalmologists should be aware that patients receiving systemic immunomodulatory therapy have a higher risk of developing Histoplasma infections. Prompt diagnosis and treatment using the expertise of an infectious diseases specialist may ensure low mortality for these patients.
引用
- Starr MR, Smith WM. Histoplasmosis Following Systemic Immunomodulatory Therapy for Ocular Inflammation. Am J Ophthalmol. 2018. PMID: 30308204. doi:10.1016/j.ajo.2018.09.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。